Hepatitis B immune globulin

Phase 3Small molecule

Hepatitis B immune globulin is one of 67 small molecule programs targeting Liver Transplant. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Liver TransplantActive, not recruiting

Chronic HepatitisActive, not recruiting

End Stage Liver DiseaseActive, not recruiting

Liver TransplantPhase 3

Active, not recruiting

Chronic HepatitisPhase 2

Active, not recruiting

End Stage Liver DiseasePhase 2

Active, not recruiting

Competition

Competitive Landscape

624 competitors in Chronic Hepatitis

#DrugCompanyPhaseTrials

PEG-Intron

Merck & Co.

Preclinical

43 2

Sovaldi

Gilead

Preclinical

34 3

Hepatitis B immune globulin

Merck & Co.

Phase 3

1 4

Virazole

CConrado Roberto Hoffmann Filho

Preclinical

199 5

Incivek

Vertex Pharmaceuticals

Preclinical

10 6

Roferon-a

Roche

Preclinical

3 7

Medrol

Pfizer

Preclinical

1 8

Dasabuvir

AbbVie

Preclinical

7 9

SOF/VEL

Gilead

Preclinical

4 10

Keyhole-Limpet Hemocyanin

Bristol-Myers Squibb

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Liver Transplant2 trials

Pilot Study to Assess the Pharmacokinetics of Intravenous Nabi 5% Hepatitis B Immune Globulin (Boca HBVIg) Used in Combination With Lamivudine for Patients With Hepatitis B Virus (HBV) Associated Liver Disease Undergoing Liver Transplantation

Completed·BBiotest Pharmaceuticals Corporation·Phase 1/2·NCT01421212·30 enrolled

Efficacy and Safety of Niuliva® for the Prevention of Hepatitis B Virus Recurrence in Newly Orthotopic Liver Transplant Recipients

Completed·IInstituto Grifols, S.A.·Phase 3·NCT01131065·15 enrolled

End Stage Liver Disease1 trial

HepeX-B in Post Hepatic Allografts for Treatment of End Stage Liver Disease Due to Hepatitis B Infection

Terminated· Merck & Co. logo

Merck & Co.·Phase 2·NCT00228592

Chronic Hepatitis1 trial

Hepatitis B Immune Globulin (HBIg) to Restore Immune Control in People With Chronic Hepatitis B

Withdrawn·NNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)·Phase 2·NCT03575208

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for Hepatitis B immune globulin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Hepatitis B immune globulin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Hepatitis B immune globulin. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Merck & Co. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Merck & Co.

Hepatitis B immune globulin

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Liver Transplant2 trials

End Stage Liver Disease1 trial

Chronic Hepatitis1 trial

References

Drug Info

Quick Facts

Related News